Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2020-04-28 Management Reports
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2019年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2019 年度监事会工作报告' which translates to '2019 Supervisory Board Work Report' of Beijing SL Pharmaceutical Co., Ltd. It details the supervisory board's activities, meetings, opinions on company operations, financial oversight, internal controls, and compliance with laws and regulations during the 2019 fiscal year. It includes review and approval of quarterly and annual reports, audit opinions, and internal control evaluations. The document is a report from the supervisory board rather than a full annual report or audit report itself. It is not a short announcement or certification but a substantive report on supervisory activities and oversight for the year. This type of document aligns best with Management Reports (MDA), which cover management's detailed explanation of financial results, business trends, and outlook, including supervisory board oversight reports. The document is 3865 characters, substantive, and focused on supervisory work and company governance for the year 2019.
2020-04-28 Chinese
2020年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a 2020 first quarter earnings forecast (业绩预告) from Beijing SL Pharmaceutical Co., Ltd. It provides estimated net profit figures for the period January 1 to March 31, 2020, and explains reasons for expected performance changes. It explicitly states that the forecast is preliminary, unaudited, and that final audited data will be disclosed in the official first quarter report. The document is short (745 characters) and serves as an earnings preview rather than a full interim report with actual financial statements. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results highlights. Q1 2020
2020-04-14 Chinese
关于第二大股东部分股权质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's second largest shareholder. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company stock, and related registration information. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledge activity, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Major Shareholding Notification (MRQ) since it concerns pledge rather than ownership threshold crossing, nor does it fit Capital/Financing Update (CAP) as it is not about new financing but about share pledge. The document length is short and it is a formal disclosure. Therefore, the best classification is Regulatory Filings (RNS).
2020-04-07 Chinese
关于第二大股东新乡白鹭投资集团有限公司股权解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the release of pledged shares by its second largest shareholder, Xinxiang Bailu Investment Group Co., Ltd. It details the number of shares released from pledge, the pledge start and release dates, and cumulative pledged shares. The content focuses on share pledge status and related shareholder information. There is no financial report, earnings data, management discussion, or regulatory certification. The document is a specific announcement about share pledge release, which fits best under the category of Major Shareholding Notification (MRQ), as it involves changes in significant share ownership or share pledge status by a major shareholder. The document length is short and it is not a report publication announcement or certification. Therefore, the classification is MRQ with high confidence.
2020-03-26 Chinese
2019年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a 2019 annual performance quick report (业绩快报) from Beijing SL Pharmaceutical Co., Ltd. It contains preliminary financial data for the year 2019, including revenue, profit, net income, earnings per share, and asset information. The data is noted as preliminary and internally audited but not yet audited by an accounting firm, indicating it is an initial earnings announcement rather than a full annual report. The document is relatively short (1579 characters) and focuses on key financial highlights and explanations of performance changes. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only, rather than a full Annual Report (10-K) or Interim Report (IR). FY 2019
2020-02-27 Chinese
关于第二大股东2020年非公开发行可交换公司债券发行完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a non-public issuance of exchangeable corporate bonds by the company's second largest shareholder. It includes details about the bond issuance, such as bond code, issuance period, amount raised, and pledge of shares as collateral. The document is relatively short (1201 characters) and serves as a formal disclosure of a financing event rather than a full financial report or detailed analysis. It does not contain financial statements or management discussion but focuses on capital raising activity and related shareholder information. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-01-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.